8-K 1 q28k73103.txt Q-2 EARNINGS RELEASE 07/31/03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2003 CURATIVE HEALTH SERVICES, INC. (Exact name of registrant as specified in its charter) Minnesota 000-19370 41-1503914 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 150 Motor Parkway Hauppauge, New York 11788-5145 (Address of principal executive offices) (631) 232-7000 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Item 12. Results of Operations and Financial Condition The following information is being furnished under Item 12, Results of Operations and Financial Condition. Such information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. On July 31, 2003, Curative Health Services, Inc. issued a press release, attached hereto as Exhibit 99.1, to report its results of operations and financial condition for the completed fiscal quarter ended June 30, 2003. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CURATIVE HEALTH SERVICES, INC. Date: July 31, 2003 By: /s/ Thomas Axmacher ----------------------- Thomas Axmacher Chief Financial Officer Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Scott Eckstein Investor Relations Curative Health Services 631-232-7044 seckstein@curativehealth.com CURATIVE HEALTH SERVICES REPORTS SECOND QUARTER 2003 RESULTS Second Quarter Revenues of $44.7 Million, GAAP Net Income Per Share of $0.26, Results Include charges of $0.04 Per Share Related to Refinancing of Credit Facility and a Corporate Structure Reorganization Hauppauge, New York - July 31, 2003 - Curative Health Services, Inc., (Nasdaq: CURE), announced today second quarter financial results for the period ended June 30, 2003. Total revenues for the second quarter were $44.7 million, compared with $31.9 million reported in the second quarter of 2002, an increase of 40.0%. GAAP net income was $3.5 million or $0.26 per diluted share, compared with GAAP net income of $2.8 million, or $0.23 per diluted share, for the second quarter of 2002. Adjusted net income for the second quarter was $4.0 million or $0.30 per diluted share. The adjusted second quarter 2003 results add back to GAAP net income after tax charges of $0.4 million ($0.6 million pre-tax), or $0.03 per diluted share after tax, associated with terminating the Company's previous credit facility upon entering into a new $40 million senior secured credit facility with GE Healthcare Financial Services during the second quarter and after tax costs incurred by the Company of approximately $0.1 million ($0.2 million pre-tax), or $0.01 per diluted share related to a proposed corporate structure reorganization. Management believes these adjustments are necessary to better present the underlying business operating results. Total revenues for the six months ended June 30, 2003 were $102.7 million. GAAP net income was $6.9 million or $0.51 per diluted share. Adjusted net income for the six months ended June 30, 2003 was $9.1 million or $0.66 per diluted share. The adjusted six month results add back to net income the charges taken during the second quarter relating to termination of the prior credit facility and to the proposed corporate structure reorganization, as well as after tax charges of $1.0 million ($1.6 million pre-tax), or $0.07 per diluted share after tax, associated with the consolidation of the Company's Specialty Pharmacy Services operations and $0.7 million after tax ($1.1 million pre-tax), or $0.05 per diluted share after tax of charges associated with settlements, including severance agreements, with former executives terminated in March 2002, that were recorded in the first quarter of 2003. (more) "Our strategy is to combine thoughtful acquisitions with organic growth initiatives to build a highly profitable specialty pharmacy over the next several years. This quarter we saw several key accomplishments," said Joseph Feshbach, Curative's Chairman and Chief Executive Officer. "We are particularly pleased with our new status as a preferred distributor for Synagis(R) by MedImmune. This is an important distinction that we believe demonstrates the high level of value our services provide to our customers in the distribution of Synagis(R) and our other therapy lines. Moreover, we believe it validates our strategy of making important commitments to specific therapies and building on this capital commitment with internal marketing resources to achieve organic growth in our acquired businesses." Highlights for the second quarter of 2003 included: o The acquisition of the specialty pharmacy business of Prescription City, Inc. for a total consideration of approximately $17.5 million. Also during the quarter, the Company acquired the assets and specialty pharmacy business of All Care Inc., a Louisiana-based Synagis(R) pharmacy for $2.0 million. o Curative completed a new $40 million senior secured credit facility with GE Healthcare Financial Services. This new credit facility, which replaced the Company's previously existing line of credit, matures on July 15, 2007. o The Company was chosen by MedImmune, Inc. as one of a select group of national home health care providers of Synagis(R). Curative has also been selected by MedImmune as a preferred regional specialty pharmaceutical distributor for Synagis(R). o In the Wound Care business, the Company signed four new multi-year contracts to manage acute care hospital Wound Care Center(R) programs and had one contract terminated. Additionally, the Company has signed one multi-year contract thus far in the third quarter. Third Quarter, Fiscal 2003 and Fiscal 2004 Guidance For the full year 2003, the Company now expects revenues to be in the range of $232-$241 million and GAAP net income per diluted share to be in the $1.31-$1.37 range. For the full year 2003, the Company expects adjusted net income per diluted share to be in the $1.46-$1.52 range. This adjusted net income per diluted share guidance excludes costs of $0.12 per diluted share the Company recorded in the first quarter 2003 relating to the consolidation of the Company's Specialty Pharmacy Services operations and charges associated with the settlements, including severance agreements, with former executives terminated in March, 2002 as well as costs of $0.04 per diluted share recorded in the second quarter 2003 related to terminating our existing credit facility and a proposed corporate structure reorganization. For the third quarter of 2003, Curative anticipates revenues in the range of approximately $48-$50 million and GAAP net income per diluted share in the range of $0.29-$0.31. For the fourth quarter 2003, the Company expects revenues of approximately $82-$88 million and GAAP net income of approximately $0.50-$0.54 per diluted share. (more) For 2004, the Company anticipates revenues of approximately $300-$320 million and earnings per diluted share to be in the range of $1.75-$1.85. Revenues for Specialty Pharmacy are expected to be in the $270-$290 million range and revenues for Specialty Healthcare Services are expected to be approximately $30 million. Specialty Pharmacy Services revenue growth is expected from both organic growth as the result of the Company's expanded sales force, as well as having acquisitions completed during the first six months of 2003 included for a full year in 2004. The Company will host a conference call to discuss the Company's second quarter 2003 financial results, recent developments, business strategy and outlook on Thursday, July 31, 2003, at 11:00 a.m. Eastern Time. To participate in the conference call, dial 1-800-915-4836 approximately 10 minutes prior to the scheduled start time. If you are unable to participate, a digital replay of the call will be available from Thursday, July 31, 2003 at 1:00 p.m. Eastern Time until 12:00 a.m. Eastern Time on August 7, 2003 by dialing 1-800-428-6051 with passcode # 300459. The live broadcast of Curative's quarterly conference call will be available online by going to www.curative.com and selecting the Investor Relations link, on www.streetevents.com, and on www.companyboardroom.com. An online replay will be available shortly after the call at those sites. About Curative Health Services Curative Health Services, Inc., through its two business units, Specialty Pharmacy Services and Specialty Healthcare Services, seeks to deliver high-quality results and exceptional patient satisfaction for patients experiencing serious or chronic medical conditions. Curative's Specialty Pharmacy Services business unit provides services to help patients manage the health care process, and offers related pharmacy products to patients for chronic and critical disease states including Hemophilia, Immune System Disorders, Respiratory Syncytial Virus (RSV), Multiple Sclerosis, Rheumatoid Arthritis and Cancer. Curative's Specialty Healthcare Services ("SHS") business unit is an industry leader in chronic wound care management. SHS provides a broad continuum of services to health care providers through a nationwide network. This national network of hospital-based Wound Care Center(R) programs has offered comprehensive treatment to over 375,000 patients. For more information, visit www.curative.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such differences include, but are not limited to, the termination or non-renewal of a material number of contracts, an inability to obtain new contracts, changes in the government regulations relating to the Company's Specialty Healthcare Services or Specialty Pharmacy Services business units, changes in the regulations governing third party reimbursements for the Company's services, manufacturing shortages of products sold by Curative's Specialty Pharmacy Services business unit, and the other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Readers of this release are referred to the Company's Annual Report on Form 10-K for the year ended December 31, 2002 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2003, for further discussion of these and other factors that could affect future results. (Tables Follow) CURATIVE HEALTH SERVICES, INC. AND SUBSIDIARIES Selected Financial Information Condensed Consolidated Statements of Operations ----------------------------------------------- (In thousands, except for per share data)
(Unaudited) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2003 2002 2003 2002 ---------------------- ------------------------------ Revenues $ 44,689 $ 31,920 $ 102,709 $ 54,684 Costs and expenses: Cost of product sales and services 28,550 20,444 69,415 34,701 Selling, general & administrative 8,950 6,610 17,295 11,533 Costs of credit facility termination and corporate structure reorganization 826 - 826 - Costs of pharmacy consolidation and executive terminations - - 2,713 - ------ ------ ------- ------ Total costs and expenses 38,326 27,054 90,249 46,234 ------ ------ ------- ------ Income from operations 6,363 4,866 12,460 8,450 Interest income 2 17 4 53 Interest expense 525 145 1,012 282 ------ ------ ------- ------ Income before income taxes 5,840 4,738 11,452 8,221 Income taxes 2,307 1,907 4,524 3,340 ------ ------ ------- ------ Net income $ 3,533 $ 2,831 $ 6,928 $ 4,881 ====== ====== ======= ====== Net income per common share, basic $ 0.29 (1) $ 0.25 $ 0.57 (1) $ 0.46 ====== ====== ======= ====== Net income per common share, diluted $ 0.26 (1) $ 0.23 $ 0.51 (1) $ 0.42 ====== ====== ======= ====== Denominator for basic earnings per share, weighted average common shares 12,378 11,536 12,299 10,582 ====== ====== ======= ====== Denominator for diluted earnings per share, weighted average common shares assuming conversions 13,797 12,349 13,864 11,608 ====== ====== ======= ======
(1) Calculated under the "as if converted" method, which requires adding shares related to convertible notes that have no contingencies to the denominator for diluted earnings per share and adding to net income, the numerator, tax effected interest expense relating to those convertible notes. CURATIVE HEALTH SERVICES, INC. AND SUBSIDIARIES Selected Financial Information Reconciliation of GAAP Net income to Adjusted net income ------------------- (In thousands, except for per share data)
(Unaudited) (Unaudited) Three Months Six Months Ended Ended June 30, 2003 June 30, 2003 ------------- ------------- GAAP Net income $ 3,533 $ 6,928 Adjustments: Costs of credit facility termination and corporate structure reorganization 826 826 Costs of pharmacy consolidation and executive terminations - 2,713 ------ ------ Subtotal 826 3,539 Tax benefit (326) (1,398) ------ ------ Adjusted net income $ 4,033 $ 9,069 ====== ====== Reconciliation of GAAP Net income per common share, diluted to Adjusted net income per common share, diluted -------------------------------------------------------- GAAP net income per common share, diluted $ 0.26 (1) $ 0.51 (1) Adjustments: Costs of credit facility termination and corporate structure reorganization 0.06 0.06 Costs of pharmacy consolidation and executive terminations - 0.19 ------ ------ Subtotal 0.06 0.25 Tax benefit (0.02) (0.10) ------ ------ Adjusted net income per common share, diluted $ 0.30 (1) $ 0.66 (1) ====== ====== Denominator for diluted earnings per share, weighted average common shares assuming conversions 13,797 13,864 ====== ======
(1) Calculated under the "as if converted" method, which requires adding shares related to convertible notes that have no contingencies to the denominator for diluted earnings per share and adding to net income, the numerator, tax effected interest expense relating to those convertible notes. CURATIVE HEALTH SERVICES, INC. AND SUBSIDIARIES Selected Financial Information Condensed Consolidated Balance Sheets ------------------------------------- (Dollars in thousands)
(Unaudited) Assets June 30, 2003 December 31, 2002 ------------- ------------------ Current assets: Cash and cash equivalents $ 998 $ 2,643 Accounts receivable, net 40,640 36,438 Deferred tax assets 3,088 2,957 Inventories 10,307 12,766 Prepaids and other current assets 2,483 2,212 ------- ------- Total current assets 57,516 57,016 Property and equipment, net 5,259 3,284 Goodwill and intangibles 148,456 125,165 Other long-term assets 1,732 979 ------- ------- Total assets $ 212,963 $ 186,444 ======= ======= Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 21,583 $ 21,786 Accrued expenses 10,540 11,579 Current portion long term liabilities 7,138 6,102 ------- ------- Total current liabilities 39,261 39,467 Long-term liabilities 44,115 26,076 Stockholders' equity 129,587 120,901 ------- ------- Total liabilities and stockholders' equity $ 212,963 $ 186,444 ======= =======
Editors Note: This release is also available on the Internet over the World Wide Web at: http://www.curative.com ----------------------- # # #